... it is a frequent complication occurring at an early stage of the disease. Background: Bone metastases in breast cancer patients lead to increased mortality and decreased health-related quality of life. Therefore, early diagnostic assessment and treatment is requested. Meanwhile the progress of the disease should...

...) months. Median time between cancer diagnosis and detection of BMs was 13.6 (7.3-52.8) months. Moreover, we observed a significant association between BMs and bone metastases (particularly vertebral lesions). Discussion: Despite the retrospective design, this is the first study evaluating the incidence...

...) with bone metastases. We also investigated the characteristics and predictive factors of skeletal-related events (SREs) in these patients. Materials and Methods: Sixty-one patients who were first diagnosed with SCLC with bone metastases at our institution were included in this retrospective analysis...

...Andrea Martoni; Monica Guaraldi; Paolo Camera; Renato Biagi; Susanna Marri; Franco Beghé; Franco Pannuti Thirty-eight normocalcemic patients with bone metastases from breast carcinoma were randomized to receive dichloromethylene diphosphonate (CL2MDP) in addition to their specific antitumor...

...C. Manegold; K. Klinga; B. Krempien; G. Schettler The purpose of our study was to clarify whether the amount of tissue extracted by means of iliac crest needle biopsy (ICNB) would suffice for a quantitative determination of estrogen receptors (ER) in bone metastases, and to see if the method...

.... Bisphosphonate 3-Amino-1-hydroxypropane-1,1-bisphosphonic acid Osteolyses Walker carcinosarcoma Osteopathy prophylaxis Bone metastases Oncology 45: 41-46 (1988) < 1988 S. K arger A G. Basel 0030 2414 88 0451 0041 $2.75 0 Protective Effects of a Prophylactic Treatment with the Bisphosphonate 3-Amino-l...

..., instructions or products referred to in the content or advertisements. Bone metastases Breast carcinoma Metastatic bone disease Carcinoma breast Bone scintiscans Oncology 36: 94-98 (1979) Bone Scintigrams: Their Clinical Usefulness in Patients with Breast Carcinoma Kwang G. Joo, K.L. Parthasarathy...

... as well as the dynamic evolution of lytic lesions to blastic healing may be appreciated. Serial bone scanning should be performed in con­ junction with standard radiographs of abnormal areas of radionuclide accumulation. Key Words. Bone scan - Bone métastasés Cancer monitor Introduction The clinical...

...Marina E. Cazzaniga; Luigi Dogliotti; Stefano Cascinu; Sandro Barni; Roberto Labianca; Silvana Chiara; Pier Franco Conte; Giampietro Gasparini; Lara Pasetto; Valter Torri Background: Little information is available about the management and clinical outcome of bone metastases (BM) in breast cancer...

... of circulating angiogenic factors, metalloproteinases and acute-phase cytokines after the first single zoledronic acid (ZA) intravenous infusion. Experimental Design: Eighteen consecutive breast cancer patients with bone metastases were evaluated for circulating levels of vascular endothelial growth factor (VEGF...

... of life in patients with metastatic bone disease who are likely to have a prolonged clinical course. Highly potent, nitrogen-containing bisphosphonates such as zoledronic acid reduce SREs in patients with bone metastases from other solid tumors (including lung cancer). Part one of our review discussed...

... in the reduction of skeletal-related complications for a number of tumors including breast, prostate and myeloma, and improvements in the quality of life for patients. There is now evidence that newer, highly potent, nitrogen-containing bisphosphonates reduce skeletal complications in patients with bone metastases...